Annual report [Section 13 and 15(d), not S-K Item 405]

Geographic and segmental information (Tables)

v3.25.1
Geographic and segmental information (Tables)
12 Months Ended
Dec. 31, 2024
Geographic and segmental information  
Schedule of long-lived assets

Long-lived assets (excluding intangibles, deferred tax and financial instruments) were located as follows (in thousands):

​

​

​

​

​

​

​

​

​

December 31, 

​

December 31, 

​

    

2024

    

2023

U.K.

​

$

24,264

​

$

40,988

U.S.

​

 

26,954

​

 

30,720

Total long-lived assets

​

$

51,218

​

$

71,708

Summary of the segment profit or loss

​

​

​

​

​

​

​

​

​

​

​

​

​

Year ended

​

​

December 31, 

​

​

2024

    

2023

​

2022

Revenue

​

$

178,032

​

$

60,281

​

$

27,148

Less:

​

​

​

​

​

​

​

​

​

Research

​

​

(13,404)

​

​

(13,228)

​

​

(22,912)

CMC and Quality

​

​

(61,350)

​

​

(60,466)

​

​

(61,850)

Biomarkers

​

​

(8,227)

​

​

(4,235)

​

​

(8,977)

Development and Compliance

​

​

(52,737)

​

​

(43,863)

​

​

(43,614)

Infrastructure management and Facilities

​

​

(31,739)

​

​

(28,481)

​

​

(25,266)

Commercial and Commercial planning

​

​

(15,860)

​

​

(3,344)

​

​

(4,329)

Support and corporate functions

​

​

(45,186)

​

​

(43,614)

​

​

(32,483)

Other segment expenses(a)

​

​

(18,289)

​

​

(2,791)

​

​

8,318

Total operating expenses

​

​

(246,792)

​

​

(200,022)

​

​

(191,113)

Operating loss

​

​

(68,760)

​

​

(139,741)

​

​

(163,965)

​

​

​

​

​

​

​

​

​

​

Interest income

​

​

6,596

​

​

5,964

​

​

1,542

Interest expense

​

​

(3,348)

​

​

—

​

​

—

Gain on bargain purchase

​

​

—

​

​

22,049

​

​

—

Other income (expense), net

​

​

(1,726)

​

​

(807)

​

​

(536)

Income tax expense

​

​

(3,576)

​

​

(1,336)

​

​

(2,497)

Segment and consolidated net loss

​

$

(70,814)

​

$

(113,871)

​

​

(165,456)